Lanthanum carbonate is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). It is available as chewable tablets and oral powder. MedsAcross supplies Lanthanum carbonate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders.
Source: US FDA prescribing information
LANTHANUM CARBONATE is a phosphate binder that reduces absorption of phosphate by forming insoluble lanthanum phosphate complexes that pass through the GI tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.
Source: US FDA prescribing information
Divide the total daily dose of LANTHANUM CARBONATE and take with or immediately after meals. The recommended initial total daily dose of LANTHANUM CARBONATE is 1,500 mg. Titrate the dose every 2 to 3 weeks until an acceptable serum phosphate level is reached. Monitor serum phosphate levels as needed during dose titration and on a regular basis thereafter. LANTHANUM CARBONATE has the potential to bind other orally administered drugs, consider separating the administration of other oral medications. In clinical studies of patients with ESRD, LANTHANUM CARBONATE doses up to 4,500 mg were evaluated. Most patients required a total daily dose between 1,500 mg and 3,000 mg to reduce plasma phosphate levels to less than 6.0 mg/dL. Doses were generally titrated in increments of 750 mg/day. Chew or crush LANTHANUM CARBONATE completely before swallowing.
Source: US FDA prescribing information
Contraindicated in patients with: - hypersensitivity to LANTHANUM CARBONATE or to any ingredient in the formulation. - bowel obstruction, including ileus and fecal impaction. Hypersensitivity to LANTHANUM CARBONATE or to any ingredient in the formulation. Bowel obstruction, ileus, and fecal impaction.
Source: US FDA prescribing information
Serious cases of gastrointestinal obstruction, ileus, subileus, gastrointestinal perforation, and fecal impaction. Risks include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications. Advise patients to chew or crush the tablet completely. LANTHANUM CARBONATE has radio-opaque properties and, therefore, may give the appearance typical of an imaging agent during abdominal X-ray procedures.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the labeling: Gastrointestinal Adverse Effects In controlled trials, the most common adverse reactions that were more frequent (≥5% difference vs. placebo) in LANTHANUM CARBONATE were nausea, vomiting, and abdominal pain. The following adverse reactions have been identified during post-approval use of LANTHANUM CARBONATE: constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet.
Source: US FDA prescribing information
There is a potential for LANTHANUM CARBONATE to interact with compounds that bind to cationic antacids (i.e., aluminum-, magnesium-, or calcium-based), therefore, do not take such compounds within 2 hours of dosing with LANTHANUM CARBONATE. Oral quinolone antibiotics must be taken at least 1 hour before or 4 hours after LANTHANUM CARBONATE. Do not take thyroid hormone replacement therapy within 2 hours of dosing with LANTHANUM CARBONATE. Monitoring of TSH levels is recommended in patients receiving both medicinal agents. For oral medications where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separation of the timing of the administration of the two drugs.
Source: US FDA prescribing information
Store LANTHANUM CARBONATE Chewable Tablets at 25°C (77°F): excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Lanthanum carbonate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lanthanum carbonate 1000 mg chewable tabletOralGeneric name | — | US FDA | Available on request |
| Lanthanum carbonate 500 mg chewable tabletOralGeneric name | — | US FDA | Available on request |
| Lanthanum carbonate 750 mg chewable tabletOralGeneric name | — | US FDA | Available on request |
| Fosrenol 1000 mg chewable tabletOral | Takeda Pharmaceuticals | US FDA | Available on request |
| Fosrenol 1000 mg oral powderOral | Takeda Pharmaceuticals | US FDA | Available on request |
| Fosrenol 500 mg chewable tabletOral | Takeda Pharmaceuticals | US FDA | Available on request |
| Fosrenol 750 mg oral powderOral | Takeda Pharmaceuticals | US FDA | Available on request |
| Fosrenol 750 mg chewable tabletOral | Takeda Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 26 October 2004 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Lanthanum carbonate in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Lanthanum carbonate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lanthanum carbonate, including Fosrenol.
Yes. The US FDA first approved Lanthanum carbonate on 26 October 2004, according to Drugs@FDA.
No listed presentation of Lanthanum carbonate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lanthanum carbonate is classified under ATC code V03AE03 (Lanthanum carbonate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.